| dbo:abstract
|
- Retinoic acid syndrome (RAS) is a potentially life-threatening complication observed in people with acute promyelocytic leukemia (APML) and first thought to be specifically associated with all-trans retinoic acid (ATRA) (also known as tretinoin) treatment. Subsequently, so-called RAS was recognized in APML patients who had been treated with another highly efficacious drug, arsenic trioxide, and yet did not appear in patients treated with tretinoin for other disorders. These facts and others support the notion that RAS depends on the presence of the malignant promyelocytes. This has led to the growing deprecation of the term 'retinoic acid syndrome' and to an increasing use of the term differentiation syndrome to signify this APML treatment complication. (en)
- レチノイン酸症候群（英: Retinoic acid syndrome、RAS）は急性前骨髄球性白血病（APML）の治療後に見られる、時に致死的な合併症である。当初はトレチノイン（all-trans レチノイン酸、ATRA）誘発性であると考えられていたが、その後三酸化二ヒ素を用いたAPML治療でも発現が認められ、さらにトレチノインを他の疾患の治療に用いた場合には認められない事が明らかとなった。これらの事実等から、RASは悪性前骨髄球依存性に発現すると思われる。そのため、このAPML治療の合併症の「レチノイン酸症候群」との呼称は分化症候群（英: differentiation syndrome）に変更されつつある。 (ja)
- La sindrome da acido retinoico (RAS, dall'acronimo in lingua inglese per retinoic acid syndrome) è una complicanza potenzialmente mortale osservata nei pazienti con leucemia promielocitica acuta, inizialmente ritenuta essere specificatamente correlata al trattamento con tretinoina. Successivamente fu osservata anche in pazienti con la stessa malattia trattati con ossido arsenioso, mentre non è mai stata osservata in pazienti trattati con tretinoina per altre malattie. Tali evidenze supportano l'ipotesi che si tratti di una condizione che dipende dalla presenza di promielociti maligni; questo ha portato a ritenere inadatto il termine sindrome da acido ritenoico, quindi sostituito con i termini sindrome da attivazione leucocitaria e sindrome da differenziazione. (it)
- 维甲酸综合症（英語：retinoic acid syndrome,RAS）是“全反式维甲酸（all-trans-retinoicacid,ATRA）综合症”的简称，是使用维甲酸治疗急性(Acute promyelocytic leukemia,APL）时发生的最严重并发症，多见于单用全反式维甲酸诱导治疗的过程中。 (zh)
|
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 3528 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:field
| |
| dbp:synonyms
|
- Differentiation syndrome (en)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Retinoic acid syndrome (RAS) is a potentially life-threatening complication observed in people with acute promyelocytic leukemia (APML) and first thought to be specifically associated with all-trans retinoic acid (ATRA) (also known as tretinoin) treatment. Subsequently, so-called RAS was recognized in APML patients who had been treated with another highly efficacious drug, arsenic trioxide, and yet did not appear in patients treated with tretinoin for other disorders. These facts and others support the notion that RAS depends on the presence of the malignant promyelocytes. This has led to the growing deprecation of the term 'retinoic acid syndrome' and to an increasing use of the term differentiation syndrome to signify this APML treatment complication. (en)
- レチノイン酸症候群（英: Retinoic acid syndrome、RAS）は急性前骨髄球性白血病（APML）の治療後に見られる、時に致死的な合併症である。当初はトレチノイン（all-trans レチノイン酸、ATRA）誘発性であると考えられていたが、その後三酸化二ヒ素を用いたAPML治療でも発現が認められ、さらにトレチノインを他の疾患の治療に用いた場合には認められない事が明らかとなった。これらの事実等から、RASは悪性前骨髄球依存性に発現すると思われる。そのため、このAPML治療の合併症の「レチノイン酸症候群」との呼称は分化症候群（英: differentiation syndrome）に変更されつつある。 (ja)
- La sindrome da acido retinoico (RAS, dall'acronimo in lingua inglese per retinoic acid syndrome) è una complicanza potenzialmente mortale osservata nei pazienti con leucemia promielocitica acuta, inizialmente ritenuta essere specificatamente correlata al trattamento con tretinoina. Successivamente fu osservata anche in pazienti con la stessa malattia trattati con ossido arsenioso, mentre non è mai stata osservata in pazienti trattati con tretinoina per altre malattie. Tali evidenze supportano l'ipotesi che si tratti di una condizione che dipende dalla presenza di promielociti maligni; questo ha portato a ritenere inadatto il termine sindrome da acido ritenoico, quindi sostituito con i termini sindrome da attivazione leucocitaria e sindrome da differenziazione. (it)
- 维甲酸综合症（英語：retinoic acid syndrome,RAS）是“全反式维甲酸（all-trans-retinoicacid,ATRA）综合症”的简称，是使用维甲酸治疗急性(Acute promyelocytic leukemia,APL）时发生的最严重并发症，多见于单用全反式维甲酸诱导治疗的过程中。 (zh)
|
| rdfs:label
|
- Sindrome da acido retinoico (it)
- レチノイン酸症候群 (ja)
- Retinoic acid syndrome (en)
- 维甲酸综合征 (zh)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageDisambiguates
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
